Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have been given an average recommendation of “Moderate Buy” by the six research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $10.75.

A number of research analysts recently commented on ZURA shares. Chardan Capital increased their target price on shares of Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Oppenheimer dropped their target price on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, March 20th. Finally, Wedbush started coverage on shares of Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 target price on the stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Allworth Financial LP purchased a new position in Zura Bio during the 4th quarter worth $30,000. Scientech Research LLC purchased a new position in Zura Bio during the 3rd quarter worth $45,000. Dimensional Fund Advisors LP purchased a new position in Zura Bio during the 4th quarter worth $123,000. Squarepoint Ops LLC purchased a new position in Zura Bio during the 3rd quarter worth $109,000. Finally, Qube Research & Technologies Ltd purchased a new position in Zura Bio during the 3rd quarter worth $138,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Price Performance

NASDAQ ZURA opened at $4.10 on Wednesday. The firm’s fifty day moving average price is $5.18 and its 200 day moving average price is $5.25. The company has a market capitalization of $389.01 million, a price-to-earnings ratio of -3.76 and a beta of 0.03. Zura Bio has a 12 month low of $0.99 and a 12 month high of $7.44.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). As a group, sell-side analysts forecast that Zura Bio will post -0.73 earnings per share for the current year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.